Primary (chemo-) radiotherapy and concomitant EGFR-inhibitor zalutumumab to patients with squamous cell carcinoma of the head and neck. Results of the randomized phase III trial DAHANCA 19

Jesper Grau Eriksen, Christian Maare, Jørgen Johansen, Hanne Primdahl, Jan Evensen, Claus Andrup Kristensen, Lisbeth Juhler Andersen, Jens Overgaard

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

OriginalsprogEngelsk
Publikationsdato2014
StatusUdgivet - 2014
Begivenhed5th world congress of IFHNOS & Annual Meeting of the AHNS - New York, USA
Varighed: 26. jul. 201430. jul. 2014
Konferencens nummer: 5

Konference

Konference5th world congress of IFHNOS & Annual Meeting of the AHNS
Nummer5
LandUSA
ByNew York
Periode26/07/201430/07/2014

Citer dette

Eriksen, J. G., Maare, C., Johansen, J., Primdahl, H., Evensen, J., Kristensen, C. A., ... Overgaard, J. (2014). Primary (chemo-) radiotherapy and concomitant EGFR-inhibitor zalutumumab to patients with squamous cell carcinoma of the head and neck. Results of the randomized phase III trial DAHANCA 19. Abstract fra 5th world congress of IFHNOS & Annual Meeting of the AHNS, New York, USA.
Eriksen, Jesper Grau ; Maare, Christian ; Johansen, Jørgen ; Primdahl, Hanne ; Evensen, Jan ; Kristensen, Claus Andrup ; Andersen, Lisbeth Juhler ; Overgaard, Jens. / Primary (chemo-) radiotherapy and concomitant EGFR-inhibitor zalutumumab to patients with squamous cell carcinoma of the head and neck. Results of the randomized phase III trial DAHANCA 19. Abstract fra 5th world congress of IFHNOS & Annual Meeting of the AHNS, New York, USA.
@conference{d68d93f90b7a48e885bb705d0803e9c9,
title = "Primary (chemo-) radiotherapy and concomitant EGFR-inhibitor zalutumumab to patients with squamous cell carcinoma of the head and neck. Results of the randomized phase III trial DAHANCA 19",
author = "Eriksen, {Jesper Grau} and Christian Maare and J{\o}rgen Johansen and Hanne Primdahl and Jan Evensen and Kristensen, {Claus Andrup} and Andersen, {Lisbeth Juhler} and Jens Overgaard",
year = "2014",
language = "English",
note = "null ; Conference date: 26-07-2014 Through 30-07-2014",

}

Eriksen, JG, Maare, C, Johansen, J, Primdahl, H, Evensen, J, Kristensen, CA, Andersen, LJ & Overgaard, J 2014, 'Primary (chemo-) radiotherapy and concomitant EGFR-inhibitor zalutumumab to patients with squamous cell carcinoma of the head and neck. Results of the randomized phase III trial DAHANCA 19', 5th world congress of IFHNOS & Annual Meeting of the AHNS, New York, USA, 26/07/2014 - 30/07/2014.

Primary (chemo-) radiotherapy and concomitant EGFR-inhibitor zalutumumab to patients with squamous cell carcinoma of the head and neck. Results of the randomized phase III trial DAHANCA 19. / Eriksen, Jesper Grau; Maare, Christian; Johansen, Jørgen; Primdahl, Hanne; Evensen, Jan; Kristensen, Claus Andrup; Andersen, Lisbeth Juhler; Overgaard, Jens.

2014. Abstract fra 5th world congress of IFHNOS & Annual Meeting of the AHNS, New York, USA.

Publikation: Konferencebidrag uden forlag/tidsskriftKonferenceabstrakt til konferenceForskningpeer review

TY - ABST

T1 - Primary (chemo-) radiotherapy and concomitant EGFR-inhibitor zalutumumab to patients with squamous cell carcinoma of the head and neck. Results of the randomized phase III trial DAHANCA 19

AU - Eriksen, Jesper Grau

AU - Maare, Christian

AU - Johansen, Jørgen

AU - Primdahl, Hanne

AU - Evensen, Jan

AU - Kristensen, Claus Andrup

AU - Andersen, Lisbeth Juhler

AU - Overgaard, Jens

PY - 2014

Y1 - 2014

M3 - Conference abstract for conference

ER -

Eriksen JG, Maare C, Johansen J, Primdahl H, Evensen J, Kristensen CA et al. Primary (chemo-) radiotherapy and concomitant EGFR-inhibitor zalutumumab to patients with squamous cell carcinoma of the head and neck. Results of the randomized phase III trial DAHANCA 19. 2014. Abstract fra 5th world congress of IFHNOS & Annual Meeting of the AHNS, New York, USA.